Shanthini Kasturi1,2, Jackie Szymonifka3,4, Jayme C Burket1,2, Jessica R Berman1,2, Kyriakos A Kirou1,2, Alana B Levine1,2, Lisa R Sammaritano1,2, Lisa A Mandl1,2. 1. From the Division of Rheumatology/Department of Medicine, Hospital for Special Surgery; Weill Cornell Medicine, New York, New York, USA. 2. S. Kasturi, MD, MS, Division of Rheumatology/Department of Medicine, Hospital for Special Surgery, and Weill Cornell Medicine; J. Szymonifka, MA, Division of Rheumatology/Department of Medicine, Hospital for Special Surgery; J.C. Burket, PhD, Healthcare Research Institute, Hospital for Special Surgery; J.R. Berman, MD, Division of Rheumatology/Department of Medicine, Hospital for Special Surgery, and Weill Cornell Medicine; K.A. Kirou, MD, Division of Rheumatology/ Department of Medicine, Hospital for Special Surgery, and Weill Cornell Medicine; A.B. Levine, MD, Division of Rheumatology/Department of Medicine, Hospital for Special Surgery, and Weill Cornell Medicine; L.R. Sammaritano, MD, Division of Rheumatology/Department of Medicine, Hospital for Special Surgery, and Weill Cornell Medicine; L.A. Mandl, MD, MPH, Division of Rheumatology/Department of Medicine, Hospital for Special Surgery and Weill Cornell Medicine. 3. From the Division of Rheumatology/Department of Medicine, Hospital for Special Surgery; Weill Cornell Medicine, New York, New York, USA. kasturis@hss.edu. 4. S. Kasturi, MD, MS, Division of Rheumatology/Department of Medicine, Hospital for Special Surgery, and Weill Cornell Medicine; J. Szymonifka, MA, Division of Rheumatology/Department of Medicine, Hospital for Special Surgery; J.C. Burket, PhD, Healthcare Research Institute, Hospital for Special Surgery; J.R. Berman, MD, Division of Rheumatology/Department of Medicine, Hospital for Special Surgery, and Weill Cornell Medicine; K.A. Kirou, MD, Division of Rheumatology/ Department of Medicine, Hospital for Special Surgery, and Weill Cornell Medicine; A.B. Levine, MD, Division of Rheumatology/Department of Medicine, Hospital for Special Surgery, and Weill Cornell Medicine; L.R. Sammaritano, MD, Division of Rheumatology/Department of Medicine, Hospital for Special Surgery, and Weill Cornell Medicine; L.A. Mandl, MD, MPH, Division of Rheumatology/Department of Medicine, Hospital for Special Surgery and Weill Cornell Medicine. kasturis@hss.edu.
Abstract
OBJECTIVE: The aims of this study were to assess the construct validity and the test-retest reliability of Patient Reported Outcomes Measurement Information System (PROMIS) computerized adaptive tests (CAT) in patients with systemic lupus erythematosus (SLE). METHODS: Adults with SLE completed the Medical Outcomes Study Short Form-36, LupusQoL-US version ("legacy instruments"), and 14 selected PROMIS CAT. Using Spearman correlations, PROMIS CAT were compared with similar domains measured with legacy instruments. CAT were also correlated with the Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) disease activity and the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI) scores. Test-retest reliability was evaluated using ICC. RESULTS: There were 204 outpatients with SLE enrolled in the study and 162 completed a retest. PROMIS CAT showed good performance characteristics and moderate to strong correlations with similar domains in the 2 legacy instruments (r = -0.49 to 0.86, p < 0.001). However, correlations between PROMIS CAT and the SELENA-SLEDAI disease activity and SDI were generally weak and statistically insignificant. PROMIS CAT test-retest ICC were good to excellent, ranging from 0.72 to 0.88. CONCLUSION: To our knowledge, these data are the first to show that PROMIS CAT are valid and reliable for many SLE-relevant domains. Importantly, PROMIS scores did not correlate well with physician-derived measures. This disconnect between objective signs and symptoms and the subjective patient disease experience underscores the crucial need to integrate patient-reported outcomes into clinical care to ensure optimal disease management.
OBJECTIVE: The aims of this study were to assess the construct validity and the test-retest reliability of Patient Reported Outcomes Measurement Information System (PROMIS) computerized adaptive tests (CAT) in patients with systemic lupus erythematosus (SLE). METHODS: Adults with SLE completed the Medical Outcomes Study Short Form-36, LupusQoL-US version ("legacy instruments"), and 14 selected PROMIS CAT. Using Spearman correlations, PROMIS CAT were compared with similar domains measured with legacy instruments. CAT were also correlated with the Safety of Estrogens in Lupus Erythematosus National Assessment-Systemic Lupus Erythematosus Disease Activity Index (SELENA-SLEDAI) disease activity and the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index (SDI) scores. Test-retest reliability was evaluated using ICC. RESULTS: There were 204 outpatients with SLE enrolled in the study and 162 completed a retest. PROMIS CAT showed good performance characteristics and moderate to strong correlations with similar domains in the 2 legacy instruments (r = -0.49 to 0.86, p < 0.001). However, correlations between PROMIS CAT and the SELENA-SLEDAI disease activity and SDI were generally weak and statistically insignificant. PROMIS CAT test-retest ICC were good to excellent, ranging from 0.72 to 0.88. CONCLUSION: To our knowledge, these data are the first to show that PROMIS CAT are valid and reliable for many SLE-relevant domains. Importantly, PROMIS scores did not correlate well with physician-derived measures. This disconnect between objective signs and symptoms and the subjective patient disease experience underscores the crucial need to integrate patient-reported outcomes into clinical care to ensure optimal disease management.
Entities:
Keywords:
PATIENT OUTCOME ASSESSMENT; QUALITY OF LIFE; SYSTEMIC LUPUS ERYTHEMATOSUS; VALIDATION STUDY
Authors: Patricia Katz; Jinoos Yazdany; Laura Trupin; Stephanie Rush; Charles G Helmick; Louise B Murphy; Cristina Lanata; Lindsey A Criswell; Maria Dall'Era Journal: Arthritis Care Res (Hoboken) Date: 2019-11-05 Impact factor: 4.794
Authors: Shanthini Kasturi; Jackie Szymonifka; Jayme C Burket; Jessica R Berman; Kyriakos A Kirou; Alana B Levine; Lisa R Sammaritano; Lisa A Mandl Journal: J Rheumatol Date: 2018-02-01 Impact factor: 4.666
Authors: Anca D Askanase; R Paola Daly; Miya Okado; Kayla Neville; Avery Pong; Leslie M Hanrahan; Joan T Merrill Journal: Health Qual Life Outcomes Date: 2019-06-07 Impact factor: 3.186
Authors: Hetanshi Naik; Jessica R Overbey; Robert J Desnick; Karl E Anderson; D Montgomery Bissell; Joseph Bloomer; Herbert L Bonkovsky; John D Phillips; Bruce Wang; Ashwani Singal; Manisha Balwani Journal: JIMD Rep Date: 2019-09-14
Authors: Brett Dietz; Patricia Katz; Maria Dall'Era; Louise B Murphy; Cristina Lanata; Laura Trupin; Lindsey A Criswell; Jinoos Yazdany Journal: Arthritis Care Res (Hoboken) Date: 2020-12-06 Impact factor: 5.178